Evolus, Inc. Common Stock (EOLS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.04
- Estimate
- -$0.07
- Surprise
- +34.2%
- Revenue (period 2026-09-30)
- $78.0M
- Score today
- 6.4/10
Revenue source: xbrl.
How the report landed
Evolus, Inc. Common Stock (EOLS) reported a narrower loss than forecast — adjusted EPS of -$0.04 against the -$0.07 estimate (a 34.2% beat on a still-unprofitable quarter).
Coverage in the report window
- Evolus Reports Q3 2026 Financial Results — fiscal.ai, 2026-11-05
- BTIG Raises Price Target on Evolus to $15 — fiscal.ai, 2026-11-05
- BTIG Maintains Buy on Evolus, Raises Price Target to $15 — benzinga, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates EOLS Sell at 6.4/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +34.2% surprise compares with a +20.0% four-quarter average. Next scheduled report: 2027-03-02.
What argues against it
- Concentration risk — Supplier: Daewoong (Jeuveau manufacturer)
- Concentration risk — Supplier: Symatese (Evolysse manufacturer)
- Quality below floor (3.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.79
- Price target
- $13.05
- Stop
- $6.32
- Upside to target
- +92.1%
- Reward-to-risk
- 8.4:1
Risk check: trading volume is running 2.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
EOLS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $448.8M
- P/E (fwd)
- 23.2
- 52-week range
- $3.86–$9.31
- Off 52-week high
- 27.0%
- RSI (14)
- 45
- Volume vs avg
- 2.78×
- Score today
- 6.4/10